

News Release

www.rohnerchem.ch

4th October 2011

Solvias and RohnerChem announce partnership for custom research and manufacturing services

BASEL/Switzerland (October 4th, 2011) – Solvias and RohnerChem bundle their combined strengths and complementary services to offer customers a seamless solution for fine chemicals and API development from route scouting to commercial production. The focus of this strategic partnership is to reduce commercialization timelines and to realize overall cost savings for customers.

The preferred but non-exclusive partnership closes the chain of services from route scouting through to commercial manufacturing. Customers will benefit from the synergy of Solvias' expertise in chemical, analytical and solid-state development and RohnerChem's experience in scale-up and commercial scale custom synthesis of complex, small molecule fine chemicals and APIs. Solvias and RohnerChem, located within a short distance of one another, have a long history of cooperation which has over the years yielded highly successful project results, one of which was even recognized with the European Outsourcing Award.

Creating value for customers

Faster commercialization and overall cost savings are achieved by considering upscaling requirements already in the preliminary optimization phases. Having one project manager as a single point of contact for all stages of development ensures that customers are well informed and that the project meets deadlines and budget.

Accelerating chemical development

Solvias applies high throughput screening methods (HTS) which have been used successfully in asymmetric homogeneous catalysis, C,X-couplings, racemate resolutions, carbonylations, hydroformylations, biocatalysis development, and various other transformations. Solvias' solid-state development group is also fully equipped to assist in developing crystallization processes, perform polymorphism studies and provide guidance in the development of the best solid form for any API. After process optimization, which can be performed either at Solvias' or at RohnerChem's Kilolab, commercial quantities can be manufactured at RohnerChem's FDA inspected facilities. The cooperation will ensure consideration of upscaling requirements from early phases onwards, resulting in reduced overall timelines.

Both companies will continue to capitalize on their strong expertise in the area of enantioselective catalysis for the efficient production of building blocks and APIs and from the ideal fit of key technologies in catalytic, high-pressure, organometallic, cryogenic and various other technology areas.

Hansjörg Walther, CEO of Solvias stated: "As a service provider, our efforts are constantly focused on adding value to our customers' businesses. The strategic partnership ideally supplements our integrated offer in chemical and analytical development and provides customers with a smooth solution from route development to commercialization."

Thomas Rosatzin, CEO of RohnerChem, commented: "Our customers will benefit substantially from this cooperation as we will be able to reduce timelines for customers and create a service platform with an extremely broad technology and asset toolbox from the first milligrams to commercial quantities."

Financial terms of the partnership were not disclosed.

About RohnerChem

RohnerChem is a Swiss custom manufacturer specializing in organic syntheses of complex molecules. The technologies include transition metal catalysis, high pressure hydrogenations, carbonylations, low-temperature reactions, handling of hydrazine and other toxic and malodorous reagents and polymerizations. Custom manufacturing with RohnerChem means technology transfer, process optimization, scale-up, piloting and large-scale production of your intermediate or active pharmaceutical ingredient based on a broad tool box of capabilities and technologies. All laboratory and large scale manufacturing is carried out according to ISO up to cGMP standards. For additional information, please visit www.rohnerchem.com.

About Solvias

Solvias offers increased capacity and profound know-how for analytical and chemical development. Its experience and proven track record provides confidence that projects will be completed expertly and on time. With its services, products and technologies Solvias provides integrated solutions to the pharmaceutical and biopharmaceutical industry worldwide. The portfolio covers:

- Analytical Services
- Biopharmaceutical Analysis
- Solid-State Services: Polymorphism, Salts, and Crystallization
- Chemical Development and API Manufacturing up to phase II
- Catalysis
- Process Analytical Technology
- Patent and Search Services

Solvias operates with more than 280 specialists as a privately-held company located in Kaiseraugst and Basel (Switzerland).

For media requests, please contact

Silke Oeschger, Marketing Communication Manager at silke.oeschger@solvias.com or +41 61 845 6141

Barbara Handschin, Communication Manager, info@rohnerchem.com, or +41 618251214